ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer
Anne Mc Leer, M. Duruisseaux, Julian Pinsolle et al. · Lung Cancer · 2017
Cited by 54 works. doi:10.1016/j.lungcan.2017.12.004
Authors
- Anne Mc Leer
- M. Duruisseaux
- Julian Pinsolle
- Sylvian Dubourd
- Julie Mondet
- Mathilde Phillips-Houlbracq
- Nelly Magnat
- Julien Fauré
- Amandine Chatagnon
- Florence de Fraipont
- Matteo Giaj Levra
- Anne‐Claire Toffart
- G. Ferretti
- Pierre L. Hainaut
- Elisabeth M. Brambilla
- Denis Moro‐Sibilot
- Sylvie Lantuéjoul
References
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
- Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
- First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
- The 2015 World Health Organization Classification of Lung Tumors
- Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
- Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
- Anchored multiplex PCR for targeted next-generation sequencing
- Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study